Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 50 percent increase over losses of $(1.00) per share from the same period last year.
Eaton For 4Q23 Anticipates Organic Growth Of 8-10% And Adjusted EPS Of $2.39-$2.49 Vs. $2.37 Consensus
The Company's fourth quarter and full year adjusted earnings guidance for 2023 is as follows:
Three months ended
December 31,
